Neuroinflammation Targeting Therapies

Migration, Crosslink

📖

Neuroinflammation Targeting Therapies

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-neuroinflammation-targ

📖 Wiki Page

therapeutic2488 wordssynced 2026-04-02

Neuroinflammation Targeting Therapies

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuroinflammation Targeting Therapies</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>Opsona/Pharma</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>Various</td>
</tr>
<tr>
<td class="label">JC-124</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Dapsone</td>
<td>Repurposed</td>
</tr>
<tr>
<td class="label">CRID3</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Plexxikon</td>
</tr>
<tr>
<td class="label">GW2580</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">Anti-CSF1R antibodies</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">TREM2 agonistic antibodies</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">TREM2 cross-linking</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">Small molecule TREM2 activators</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Etanercept</td>
<td>

...

Neuroinflammation Targeting Therapies

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuroinflammation Targeting Therapies</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>Opsona/Pharma</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>Various</td>
</tr>
<tr>
<td class="label">JC-124</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Dapsone</td>
<td>Repurposed</td>
</tr>
<tr>
<td class="label">CRID3</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Plexxikon</td>
</tr>
<tr>
<td class="label">GW2580</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">Anti-CSF1R antibodies</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">TREM2 agonistic antibodies</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">TREM2 cross-linking</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">Small molecule TREM2 activators</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Etanercept</td>
<td>Fusion protein</td>
</tr>
<tr>
<td class="label">Infliximab</td>
<td>Chimeric antibody</td>
</tr>
<tr>
<td class="label">Adalimumab</td>
<td>Human antibody</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Anakinra</td>
<td>IL-1 receptor antagonist</td>
</tr>
<tr>
<td class="label">Canakinumab</td>
<td>IL-1β antibody</td>
</tr>
<tr>
<td class="label">Lutikizumab</td>
<td>IL-1β/α dual antibody</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>IL-6R</td>
</tr>
<tr>
<td class="label">Sarilumab</td>
<td>IL-6R</td>
</tr>
<tr>
<td class="label">Siltuximab</td>
<td>IL-6</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Dapansutrile PD</td>
<td>Dapansutrile</td>
</tr>
<tr>
<td class="label">TREM2 AD</td>
<td>AL002/AL003</td>
</tr>
<tr>
<td class="label">CSF1R PD</td>
<td>PLX5622</td>
</tr>
<tr>
<td class="label">IL-6 PD</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">NLRP3 inhibitors</td>
<td>Direct mechanism, oral bioavailability</td>
</tr>
<tr>
<td class="label">CSF1R antagonists</td>
<td>Microglial depletion possible</td>
</tr>
<tr>
<td class="label">TREM2 modulators</td>
<td>Enhances phagocytosis</td>
</tr>
<tr>
<td class="label">Cytokine inhibition</td>
<td>Well-established targets</td>
</tr>
<tr>
<td class="label">NF-κB inhibitors</td>
<td>Downstream targeting</td>
</tr>
</table>

Neuroinflammation is a central pathological feature of Parkinson's disease, with activated [microglia](/cell-types/microglia) contributing to dopaminergic neuron loss. Multiple therapeutic strategies target microglial activation, inflammasome signaling, and pro-inflammatory cytokines to reduce neuroinflammation and slow disease progression. This page covers the therapeutic landscape targeting neuroinflammation mechanisms in PD and related neurodegenerative diseases.

The neuroinflammation therapeutic field has evolved substantially over the past decade, moving from broad immunosuppression toward precision targeting of specific inflammatory pathways. Key targets include the [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome), [TREM2 signaling](/mechanisms/trem2-microglia-pathway-alzheimers), [CSF1R signaling](/mechanisms/microglial-metabolic-reprogramming), and various cytokine pathways including TNF-α, IL-1β, and IL-6.

Neuroinflammation is not merely a secondary consequence of neurodegeneration but actively drives disease progression through multiple mechanisms[@glass2010]. Understanding the complex interplay between microglial activation, protein pathology, and neuronal death provides therapeutic opportunities that may modify disease progression rather than just alleviating symptoms.

Neuroinflammation in PD

Microglial Activation

In PD, chronic microglial activation results from multiple converging pathological stimuli:

Alpha-synuclein aggregation and release: Pathological [alpha-synuclein](/proteins/alpha-synuclein) aggregates can be internalized by microglia, triggering Toll-like receptor (TLR) activation and pro-inflammatory responses[@perez2022]. Extracellular alpha-synuclein acts as a danger-associated molecular pattern (DAMP), engaging TLR2 and TLR4 to initiate NF-κB signaling and cytokine production.
Mitochondrial dysfunction: Impaired mitochondrial function in dopaminergic neurons leads to release of mitochondrial DAMPs (mito-DAMPs), including mitochondrial DNA and formyl peptides, which activate microglial NLRP3 inflammasome[@goldberg2023]. The [PINK1-Parkin mitophagy pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons) defects in familial PD contribute to accumulation of dysfunctional mitochondria that amplify neuroinflammation.
Environmental toxins: Exposure to environmental toxins such as MPTP, rotenone, and paraquat can directly activate microglia and induce neuroinflammation. These toxins share the property of targeting mitochondrial complex I, linking mitochondrial dysfunction to inflammatory responses.
Peripheral immune infiltration: Blood-brain barrier (BBB) breakdown in PD allows infiltration of peripheral immune cells including monocytes, T cells, and B cells, contributing to neuroinflammation[@henchcliffe2022]. The [blood-brain-barrier dysfunction pathway](/mechanisms/blood-brain-barrier-dysfunction) is increasingly recognized as a key contributor to neuroinflammation.

Activated microglia release a constellation of neurotoxic molecules:

Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-18 — these cytokines create a self-perpetuating inflammatory loop, activating additional microglia and promoting neuronal dysfunction[@perez2022]
Reactive oxygen species (ROS): NADPH oxidase-derived superoxide and other ROS cause direct oxidative damage to neurons and lipids, proteins, and DNA
Nitric oxide (NO): Inducible nitric oxide synthase (iNOS) produces NO, which reacts with superoxide to form peroxynitrite, a highly reactive oxidant
Excitatory amino acids: Glutamate release from activated microglia contributes to excitotoxicity

Microglial Phenotypes and Heterogeneity

Microglia exist on a spectrum of activation states, and their phenotypic heterogeneity is increasingly recognized as critical to disease outcomes[@gates2024]:

Pro-inflammatory (M1-like) phenotype:

Characterized by high CD16, CD32, CD86 expression
Produces high levels of pro-inflammatory cytokines
Associated with tissue damage and neuronal loss
Predominant in early to mid-stage disease

Anti-inflammatory (M2-like) phenotype:

Characterized by high CD206, Arg1 expression
Produces anti-inflammatory cytokines (IL-10, TGF-β)
Promotes tissue repair and phagocytosis
May be dysregulated in chronic disease

Disease-associated microglia (DAM):

Unique transcriptional signature identified in neurodegenerative disease
Upregulated TREM2, APOE signaling
Associated with amyloid and tau pathology
Represent potential therapeutic target

The concept of microglial senescence has also emerged, with aged microglia showing reduced phagocytic capacity and increased inflammatory tone[@butovsky2015]. This senescence may contribute to accumulation of pathological proteins and failure of protective responses.

Inflammasome Involvement

The NLRP3 inflammasome is a key driver of neuroinflammation in PD[@goldberg2023]:

Activation triggers: Alpha-synuclein aggregates, mitochondrial ROS, ATP release from damaged neurons, and uric acid crystals all activate NLRP3
Signaling cascade: NLRP3 activation leads to caspase-1 activation and maturation of pro-inflammatory cytokines IL-1β and IL-18
Chronic inflammation: The inflammasome creates a self-sustaining inflammatory cycle in the PD brain, with continuous IL-1β release promoting ongoing microglial activation
Peripheral NLRP3: Systemic NLRP3 activation may also contribute to central inflammation through circulating cytokines

The [NLRP3 inflammasome pathway](/mechanisms/nlrp3-inflammasome-pathway-neurodegeneration) provides multiple therapeutic targeting opportunities.

Neuroinflammation-Tau Interaction

Emerging evidence demonstrates bidirectional relationships between neuroinflammation and protein pathology[@cunningham2022]:

Tau-mediated inflammation: Pathological tau can activate microglia through TREM2-independent pathways, while inflammation accelerates tau pathology through kinase activation[@han2019]
Alpha-synuclein inflammation loop: Neuroinflammation promotes [alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation-pathway) through kinase activation, while aggregated synuclein reciprocally drives inflammation
Inflammation as disease amplifier: Neuroinflammation may represent the final common pathway linking diverse disease triggers to neuronal death

Therapeutic Approaches

NLRP3 Inhibitors

The NLRP3 inflammasome represents one of the most promising targets for neuroinflammation modulation[@stahl2023].

Dapansutrile has advanced the furthest in clinical development:

Oral bioavailability with good brain penetration in preclinical models
Phase 2 trials in osteoarthritis demonstrated favorable safety
Ongoing Phase 2 in PD to assess motor outcomes and biomarkers
Reduces IL-1β and IL-18 production in human trials
Shown to reduce neuroinflammation in animal models of PD

MCC950 is a highly potent NLRP3 inhibitor but faced development challenges:

Excellent potency in cellular and animal models
Limited brain penetration in early studies
New formulations are being developed to improve CNS exposure
Identified as a promising backup candidate

Microglial Modulation

The following diagram illustrates the therapeutic targeting points in the neuroinflammation cascade:

Mermaid diagram (expand to render)

CSF1R Antagonists

Colony-stimulating factor 1 receptor (CSF1R) is critical for microglial survival and proliferation[@schwartz2023]:

Rationale: Microglial depletion followed by repopulation with "younger" microglia may reset the inflammatory state. Studies in AD models show that PLX5622 reduces plaque-associated inflammation and improves cognitive function. In PD models, CSF1R inhibition has shown protection of dopaminergic neurons.

Clinical considerations:

Complete microglial depletion may have unintended consequences
Partial modulation may be preferable to full depletion
Effect on peripheral immune cells must be considered

TREM2 Modulators

Triggering receptor on myeloid cells 2 (TREM2) plays a complex role in neurodegeneration[@davis2023]:

TREM2 activation: Promotes microglial phagocytosis of pathological proteins (alpha-synuclein, amyloid, tau)
TREM2 dysfunction: Reduced TREM2 function leads to impaired clearance and increased pathology
Therapeutic approach: TREM2 agonism may enhance beneficial microglial functions[@colonna2017]

TREM2 antibodies in Alzheimer's disease (e.g., AL002) have advanced to Phase 2/3 trials, with readouts expected in 2024-2025[@ulrich2022]. The role of TREM2 in PD is still being clarified, with both protective and pathogenic roles proposed.

Minocycline

The tetracycline antibiotic minocycline has been extensively studied for neuroprotection:

Mechanism: Inhibits microglial activation, MMP inhibition, anti-apoptotic effects
Clinical trials: Mixed results in PD — some trials showed slowing of motor progression, others were negative
Current status: Generally not recommended as monotherapy due to inconsistent efficacy

Cytokine Inhibition

Targeting specific pro-inflammatory cytokines offers another therapeutic approach:

TNF-α Inhibition

Challenge: TNF-α inhibitors are large molecules that may have limited BBB penetration. Studies using intranasal or intraventricular delivery are being explored.

IL-1β Inhibition

IL-6 Inhibition

Neuroinflammation Pathway Inhibitors

Beyond direct cytokine targeting, several pathway-level inhibitors are in development:

NF-κB inhibitors: Block downstream inflammatory signaling
JAK-STAT inhibitors: Interrupt cytokine receptor signaling
p38 MAPK inhibitors: Reduce inflammatory kinase activity
cGAS-STING inhibitors: Block cytosolic DNA sensing pathway [related to cGAS-STING pathway in AD](/mechanisms/cgas-sting-ad-pathway)

Clinical Development Landscape

Ongoing Clinical Trials

Biomarker Development

Neuroinflammation biomarker development is critical for clinical trials[@boche2023]:

PET imaging: [TSPO PET imaging](/mechanisms/tspo-pet-imaging-neuroinflammation) measures microglial activation in vivo
Fluid biomarkers: IL-1β, IL-6, TNF-α in CSF and plasma; neurofilament light chain (NfL) for neurodegeneration
Microglial markers: TREM2, soluble TREM2 (sTREM2) in CSF
Emerging: NLRP3-associated ASC specks in extracellular vesicles

Mechanism of Action Summary

Neuroinflammation-targeting therapies work through several mechanisms:

Blocking inflammasome assembly: NLRP3 inhibitors prevent ASC oligomerization and caspase-1 activation

Reducing cytokine production: Direct cytokine inhibitors block downstream effects of inflammation

Promoting anti-inflammatory microglial phenotype: TREM2 modulators and CSF1R antagonists can shift microglia toward neuroprotective M2-like state

Enhancing microglial clearance functions: Certain approaches enhance phagocytosis of pathological proteins

Modulating peripheral immunity: Some strategies target the peripheral immune component of neuroinflammation

Combination Therapy Rationale

Neuroinflammation therapies may be particularly effective in combination:

Synergy with neuroprotective agents: Combining anti-inflammatory with disease-modifying approaches (e.g., [LRRK2 inhibitors](/therapeutics/lrrk2-kinase-targeting-therapies), [α-synuclein-targeting](/therapeutics/alpha-synuclein-immunotherapies))
Adjunct to cell replacement: Reducing inflammation may improve survival of [dopamine neuron transplants](/therapeutics/dopamine-cell-therapy-parkinsons)
Multi-target approaches: Simultaneous inhibition of multiple inflammatory pathways

Rationale for Targeting

Pathological evidence: Activated microglia are consistently found in PD substantia nigra and correlate with disease severity

Mechanistic convergence: Multiple triggers (genetic, environmental, aging) converge on neuroinflammation

Therapeutic window: Modulation rather than full suppression may preserve protective immune functions

Combination potential: Synergistic with neuroprotective and dopaminergic approaches

Key Challenges and Future Directions

Challenges

BBB penetration: Many anti-inflammatory agents are large molecules with limited brain access

Biomarker validation: Need for non-invasive markers of treatment response

Patient selection: Identifying patients most likely to benefit from anti-inflammatory therapy

Timing: Optimal intervention point in disease progression

Off-target effects: Suppressing beneficial immune functions

Complexity of microglial biology: The dual role of microglia in both driving pathology and providing protection complicates therapeutic targeting

Chronicity: Neuroinflammation is self-sustaining once established, making intervention timing critical

Emerging Approaches

Microglia repopulation: After depletion, new microglia may have improved function
Targeted delivery: Focused ultrasound for enhanced CNS drug delivery
Gene therapy: Viral vector-based expression of anti-inflammatory proteins
Cell-type specific targeting: Approaches that specifically modulate disease-associated microglia
Pro-resolving mediators: Lipid mediators that actively resolve inflammation rather than just suppress it
NLRP3-specific delivery: Nanoparticle-based targeting of NLRP3 inhibitors to microglia

Preclinical to Clinical Translation

Key Learnings from Preclinical Studies

NLRP3 inhibitors show robust protection in animal models of PD
Timing of intervention is critical - earlier is generally more effective
Combination approaches outperform monotherapy in preclinical models
Microglial depletion is achievable but must be carefully managed

Clinical Trial Design Considerations

Patient selection based on inflammatory biomarkers
Biomarker-driven dose selection
Extended treatment durations to assess disease modification
Combination arms to test synergy with other agents

Economic and Access Considerations

Generic anti-inflammatory agents may provide affordable treatment options
Repurposing existing drugs can accelerate clinical development
Biomarker-guided patient selection may improve cost-effectiveness
Early intervention may reduce long-term healthcare costs

Personalized Medicine Approaches

Biomarker-Driven Patient Selection

Future neuroinflammation-targeted therapies will likely require biomarker stratification:

TSPO polymorphism: TSPO binding affinity varies by genotype, affecting PET interpretation
Genetic risk scores: Polygenic risk for neuroinflammation may predict treatment response
Baseline inflammatory markers: Elevated IL-6, CRP may predict response to anti-IL-6 therapy
Proteomic signatures: Novel protein panels may identify patients who will benefit most

Precision Targeting

Understanding individual inflammatory profiles will enable personalized approaches:

Targeted inhibition: Match specific inflammatory pathway to patient profile
Combination optimization: Tailor combination therapy based on inflammatory signature
Dosing individualization: Biomarker-guided dosing for optimal CNS exposure
Monitoring adaptation: Dynamic biomarker monitoring to adjust treatment

Comparative Effectiveness

Comparison of Therapeutic Approaches

Network Analysis of Inflammatory Pathways

Understanding the interconnected nature of inflammatory signaling:

Redundancy: Multiple pathways can compensate for single-target inhibition
Feedback loops: Cytokine networks create self-sustaining inflammation
Cell-type specificity: Different cell types contribute differently to inflammation
Temporal dynamics: Inflammatory profiles change with disease progression

[Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
[NLRP3 Inhibitors](/therapeutics/nlrp3-inhibitors-neurodegeneration)
[TREM2 Therapies](/therapeutics/trem2-therapeutics)
[Microglial Modulation](/therapeutics/microglial-modulation-therapies)
[Microglia Pathway](/mechanisms/microglia-neuroinflammation)
[NLRP3 Inflammasome Pathway](/mechanisms/nlrp3-inflammasome-pathway-neurodegeneration)
[Complement System in Neurodegeneration](/mechanisms/complement-system-neurodegeneration)
[Blood-Brain Barrier Dysfunction](/mechanisms/blood-brain-barrier-dysfunction)
[Toll-like Receptor Signaling](/mechanisms/toll-like-receptor-signaling-neurodegeneration)
[NF-κB Signaling in Neurodegeneration](/mechanisms/nf-kappa-b-signaling-neurodegeneration)

Last updated: 2026-03-26

References

[Perez et al., Neuroinflammation in Parkinson's disease: targeting microglial activation (2022)](https://doi.org/10.1038/s41582-022-00689-8)

[Henchcliffe et al., The role of microglia and neuroinflammation in Parkinson's disease (2022)](https://doi.org/10.3233/JPD-223374)

[Kelley et al., The NLRP3 inflammasome: an overview of the mechanism of activation and regulation (2019)](https://doi.org/10.1186/s12974-019-1524-2)

[Goldberg et al., NLRP3 inflammasome activation in Parkinson's disease (2023)](https://doi.org/10.1038/s41593-023-01289-3)

[Cunningham et al., Microglial activation drives tau pathology in Alzheimer's disease (2022)](https://doi.org/10.1038/s41582-022-00647-9)

[Davis et al., TREM2 in neurodegenerative disease: from biology to therapy (2023)](https://doi.org/10.1038/s41573-023-00673-9)

[Schwartz et al., CSF1R inhibition as a therapeutic strategy for neurodegenerative diseases (2023)](https://doi.org/10.1038/s41582-023-00776-9)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Senescent Cell Mitochondrial DNA Release](/hypothesis/h-1a34778f) — 0.60 · Target: CGAS/STING1/DNASE2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-neuroinflammation-targeting-therapies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-neuroinflammation-targeting-therapies
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-89096376cc87
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neuroinflammation-targeting-therapies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

39

Outgoing

75

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroinflammation Targeting Therapies

Neuroinflammation Targeting Therapies

Overview

Neuroinflammation Targeting Therapies

Overview

Neuroinflammation in PD

Microglial Activation

Microglial Phenotypes and Heterogeneity

Inflammasome Involvement

Neuroinflammation-Tau Interaction

Therapeutic Approaches

NLRP3 Inhibitors

Microglial Modulation

CSF1R Antagonists

CSF1R Antagonists

TREM2 Modulators

Minocycline

Cytokine Inhibition

TNF-α Inhibition

IL-1β Inhibition

IL-6 Inhibition

Neuroinflammation Pathway Inhibitors

Clinical Development Landscape

Ongoing Clinical Trials

Biomarker Development

Mechanism of Action Summary

Combination Therapy Rationale

Rationale for Targeting

Key Challenges and Future Directions

Challenges

Emerging Approaches

Preclinical to Clinical Translation

Key Learnings from Preclinical Studies

Clinical Trial Design Considerations

Economic and Access Considerations

Personalized Medicine Approaches

Biomarker-Driven Patient Selection

Precision Targeting

Comparative Effectiveness

Comparison of Therapeutic Approaches

Network Analysis of Inflammatory Pathways

Related Pages

References

Related Hypotheses

💬 Discussion